Literature DB >> 18473938

E-cadherin upregulation as a therapeutic goal in cancer treatment.

E W Howard1, K D Camm, Y C Wong, X H Wang.   

Abstract

We review the role of E-cadherin in cancer progression, and its therapeutic restoration as a strategy to suppress metastasis. We subsequently discuss E-cadherin upregulating drugs, proposing a schema for restoring E-cadherin by targeting its epigenetic and transcriptional regulators. These pathways will likely provide significant future treatment breakthroughs against cancer metastasis.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18473938     DOI： 10.2174/138955708784223521

Source DB:  PubMed          Journal:  Mini Rev Med Chem        ISSN： 1389-5575            Impact factor:   3.862


  12 in total

1.  Inflammatory mediators, tumor necrosis factor-α and interferon-γ, induce EMT in human PTC cell lines.

Authors:  Nannan Lv; Yun Gao; Haixia Guan; Dan Wu; Shuangning Ding; Weiping Teng; Zhongyan Shan
Journal:  Oncol Lett       Date:  2015-07-21       Impact factor: 2.967

2.  Epigenetic activation of E-cadherin is a candidate therapeutic target in human hepatocellular carcinoma.

Authors:  Xuemei Qiu; Fengchang Qiao; Xianwei Su; Zhujiang Zhao; Hong Fan
Journal:  Exp Ther Med       Date:  2010-05-01       Impact factor: 2.447

3.  Metformin mediated reversal of epithelial to mesenchymal transition is triggered by epigenetic changes in E-cadherin promoter.

Authors:  Poulomi Banerjee; Harshini Surendran; Debabani Roy Chowdhury; Karthik Prabhakar; Rajarshi Pal
Journal:  J Mol Med (Berl)       Date:  2016-08-17       Impact factor: 4.599

4.  Increased incidence of endometrioid tumors caused by aberrations in E-cadherin promoter of mismatch repair-deficient mice.

Authors:  Irina V Kovtun; Kimberly J Harris; Aminah Jatoi; Dragan Jevremovic
Journal:  Carcinogenesis       Date:  2011-05-05       Impact factor: 4.944

5.  Detection of differentially expressed basal cell proteins by mass spectrometry.

Authors:  Viktor Todorović; Bhushan V Desai; Richard A Eigenheer; Taofei Yin; Evangeline V Amargo; Milan Mrksich; Kathleen J Green; Melanie J Schroeder Patterson
Journal:  Mol Cell Proteomics       Date:  2009-11-30       Impact factor: 5.911

6.  MicroRNA, hsa-miR-200c, is an independent prognostic factor in pancreatic cancer and its upregulation inhibits pancreatic cancer invasion but increases cell proliferation.

Authors:  Jun Yu; Kenoki Ohuchida; Kazuhiro Mizumoto; Norihiro Sato; Tadashi Kayashima; Hayato Fujita; Kouhei Nakata; Masao Tanaka
Journal:  Mol Cancer       Date:  2010-06-28       Impact factor: 27.401

7.  Development of flexible-heteroarotinoids for kidney cancer.

Authors:  Tongzu Liu; Chioniso Patience Masamha; Shylet Chengedza; K Darrell Berlin; Stan Lightfoot; Feng He; Doris Mangiaracina Benbrook
Journal:  Mol Cancer Ther       Date:  2009-05-05       Impact factor: 6.261

8.  RNAi-mediated knock-down of arylamine N-acetyltransferase-1 expression induces E-cadherin up-regulation and cell-cell contact growth inhibition.

Authors:  Jacky M Tiang; Neville J Butcher; Carleen Cullinane; Patrick O Humbert; Rodney F Minchin
Journal:  PLoS One       Date:  2011-02-09       Impact factor: 3.240

9.  Id2 promotes the invasive growth of MCF-7 and SKOV-3 cells by a novel mechanism independent of dimerization to basic helix-loop-helix factors.

Authors:  Yuanguang Meng; Chenglei Gu; Zhiqiang Wu; Yali Zhao; Yiling Si; Xiaobing Fu; Weidong Han
Journal:  BMC Cancer       Date:  2009-03-04       Impact factor: 4.430

10.  Correlation between Slug transcription factor and miR-221 in MDA-MB-231 breast cancer cells.

Authors:  Elisabetta Lambertini; Andrea Lolli; Federica Vezzali; Letizia Penolazzi; Roberto Gambari; Roberta Piva
Journal:  BMC Cancer       Date:  2012-10-02       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.